InDex Pharmaceuticals, R&D-day, 2020

Speakers: CEO Peter Zerhouni, CMO Thomas Knittel, COO Pernilla Sandwall, InDex Pharmaceuticals, Professor William J. Sandborn, University of California San Diego, Jonas Ericsson, Board Member of the Swedish patient association Mag- och tarmförbundet, Professor Raja Atreya, University of Erlangen-Nürnberg, and David Cotterell, Managing Director at Apex Healthcare Consulting

Program for InDex Pharmaceuticals’ virtual R&D Day on December 8, 15:30-17:30 CET

The purpose of the R&D day is to provide an overview of ulcerative colitis and the drug candidate cobitolimod from a scientific and market perspective. Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist under development by InDex as a novel therapy for moderate to severe ulcerative colitis. After meeting the primary endpoint in the phase IIb study CONDUCT with an outstanding combination of efficacy and safety, InDex is planning to start a phase III study with cobitolimod in the second quarter of 2021.

Introduction and welcome
Peter Zerhouni, CEO, InDex Pharmaceuticals

Ulcerative colitis – a debilitating disease with high unmet medical need
Professor William J. Sandborn, Division of Gastroenterology, University of California San Diego, California, USA

Living with ulcerative colitis – the patient perspective
Jonas Ericsson, ulcerative colitis patient and board member of the Swedish patient association Mag- och tarmförbundet

Cobitolimod – a late stage first-in-class immunotherapeutic
Professor Raja Atreya, Department of Medicine, University of Erlangen-Nürnberg, Erlangen, Germany

Planned phase III program with cobitolimod
Thomas Knittel, CMO and Pernilla Sandwall, COO, InDex Pharmaceuticals

Feedback from IBD specialists and payers on cobitolimod through primary market research
David Cotterell, Managing Director, Apex Healthcare Consulting

The commercial potential of cobitolimod
Peter Zerhouni, CEO, InDex Pharmaceuticals

Questions and Answers